摘要
目的 :观察抗CD2 0单抗联合环磷酰胺、长春新碱、阿霉素及泼尼松治疗初诊的弥漫性大B细胞淋巴瘤 (DLBL)的临床疗效。方法 :2 0 0 2 0 4 - 2 0 0 3 0 2 ,5 2例病人进入本研究。化疗采用标准的CHOP方案 :环磷酰胺 6 0 0mg/m2 (第 1天 ) ,长春新碱 1.4mg/m2 (第 1天 ) ,阿霉素 2 5mg/m2 (第 1天 )和泼尼松 6 0mg/d(第 1～ 5天 ) ,每 3周 1个疗程 ,共 6个疗程。利妥昔单抗静脉滴注剂量为 375mg/m2 ,每周或每 3周输注 1次 ,连续 4次或 6次。结果 :在 5 0例患者中 ,6 0 %获得完全反应 (CR) ,总有效率 (OR)为 10 0 %。 5 0例患者共随访了 2～ 30周 ,患者 16周的疾病无进展生存 (PFS)率为 87.3%。主要不良反应为输注相关的不良反应 (32 % )和化疗相关的血液学毒副反应 (2 0 % )。结论 :利妥昔单抗联合CHOP方案可有效用于治疗新诊断的弥漫性大B细胞性淋巴瘤具有较高的缓解率 ,不良反应较少。
Objective: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP regimen) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). Methods: 2002-04-2003-02, 52 patients were enrolled in this study. Chemotherapy was conducted with cyclophosphamide 600 mg·m -2 , vincristine 1.4 mg·m -2 , docorubicin 25 mg·m -2 on d1 and prednisone 60 mg·d -1 for successive 5 d, every 3 weeks, for 6 courses. Rituximab was given at the dose of 375 mg·m -2 every 1 or 3 weeks, for 4 or 6 courses. Results: In 50 patients who were evaluated for efficacy, complete response rate and overall response rate were achieved at 60% and 100%, respectively. 50 patients were followed-up for 2～30 weeks (mean 8±5) and estimated progress free survival (PFS) rate of 16 weeks was 87%. The regimen could be well tolerated, and the major adverse reactions were infusion-related response (32%) and hematological toxicities (20%). Conclusion: Rituximab in combined with CHOP can be successfully applied to the therapy of initially diagnosed diffuse large B cell lymphoma, with adverse reactions.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
2003年第3期157-160,共4页
Chinese Journal of Cancer Biotherapy
